[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

PE20211376A1 - Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham - Google Patents

Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham

Info

Publication number
PE20211376A1
PE20211376A1 PE2021000080A PE2021000080A PE20211376A1 PE 20211376 A1 PE20211376 A1 PE 20211376A1 PE 2021000080 A PE2021000080 A PE 2021000080A PE 2021000080 A PE2021000080 A PE 2021000080A PE 20211376 A1 PE20211376 A1 PE 20211376A1
Authority
PE
Peru
Prior art keywords
ham
htlv
therapeutic
associated myelopathy
prophylactic agent
Prior art date
Application number
PE2021000080A
Other languages
English (en)
Inventor
Kaoru Uchimaru
Makoto Yamagishi
Izumi Ishizaki
Yoshihisa Yamano
Original Assignee
Univ School St Marianna Medicine
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ School St Marianna Medicine, Univ Tokyo filed Critical Univ School St Marianna Medicine
Publication of PE20211376A1 publication Critical patent/PE20211376A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proporciona un agente terapeutico o profilactico para la Mielopatia asociada al HTLV-1 (HAM), que comprende una sustancia que inhibe el RGMa, y un metodo para el tratamiento de la Mielopatia asociada al HTLV-1 (HAM), que comprende la administracion de una cantidad farmacologicamente efectiva de una sustancia que inhibe el RGMa a un paciente con la HAM en necesidad del mismo.
PE2021000080A 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham PE20211376A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Ｈｔｌｖ－１関連脊髄症（ｈａｍ）治療又は予防剤、及びｈａｍの治療方法

Publications (1)

Publication Number Publication Date
PE20211376A1 true PE20211376A1 (es) 2021-07-27

Family

ID=69163691

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000080A PE20211376A1 (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham

Country Status (16)

Country Link
US (1) US20210269535A1 (es)
EP (1) EP3824907A4 (es)
JP (3) JP7150286B2 (es)
KR (1) KR20210034055A (es)
CN (4) CN116942831A (es)
AU (1) AU2019306721B2 (es)
BR (1) BR112021000949A2 (es)
CA (1) CA3112511A1 (es)
IL (1) IL280257A (es)
MX (1) MX2021000732A (es)
PE (1) PE20211376A1 (es)
PH (1) PH12021550134A1 (es)
SG (1) SG11202100561QA (es)
TW (2) TW202408577A (es)
WO (1) WO2020017629A1 (es)
ZA (1) ZA202101113B (es)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
JP5519642B2 (ja) 2008-09-02 2014-06-11 東レバッテリーセパレータフィルム株式会社 微多孔性高分子膜、かかる膜の作製方法、およびそれを用いたバッテリーセパレータフィルム
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−ｉ関連脊髄症を治療または予防するための医薬、およびｈｔｌｖ−ｉ関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 Ｔ 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 ｔ 세포 활성화 저해 물질의 스크리닝 방법
EP3636274B1 (en) * 2011-01-18 2024-07-17 Bioniz Therapeutics, Inc. Compositions for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Ｈｔｌｖ−１関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
ES2927550T3 (es) * 2012-07-06 2022-11-08 Univ School St Marianna Medicine Remedio para pacientes con mielopatía asociada a HTLV-1
EP3191847A1 (en) 2014-09-10 2017-07-19 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
JP2019517480A (ja) * 2016-06-01 2019-06-24 アッヴィ・インコーポレイテッド 脊髄損傷及び疼痛を処置するための抗ＲＧＭａ（Ｒｅｐｕｌｓｉｖｅ Ｇｕｉｄａｎｃｅ Ｍｏｌｅｃｕｌｅ Ａ）アンタゴニスト抗体
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Also Published As

Publication number Publication date
TW202408577A (zh) 2024-03-01
BR112021000949A2 (pt) 2021-04-27
PH12021550134A1 (en) 2021-09-27
AU2019306721B2 (en) 2024-09-05
US20210269535A1 (en) 2021-09-02
EP3824907A4 (en) 2022-05-04
WO2020017629A1 (ja) 2020-01-23
JP7150286B2 (ja) 2022-10-11
ZA202101113B (en) 2022-07-27
TWI825131B (zh) 2023-12-11
MX2021000732A (es) 2021-04-28
JP2022180487A (ja) 2022-12-06
KR20210034055A (ko) 2021-03-29
EP3824907A1 (en) 2021-05-26
JP2024095754A (ja) 2024-07-10
IL280257A (en) 2021-03-25
CN116850291A (zh) 2023-10-10
CN116942831A (zh) 2023-10-27
JP7475011B2 (ja) 2024-04-26
SG11202100561QA (en) 2021-02-25
AU2019306721A1 (en) 2021-03-11
TW202019482A (zh) 2020-06-01
JPWO2020017629A1 (ja) 2021-08-02
CA3112511A1 (en) 2020-01-23
CN112566664A (zh) 2021-03-26
CN116785439A (zh) 2023-09-22
CN112566664B (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
CL2019000268A1 (es) Composición de cannabis.
ECSP17077930A (es) Métodos y kits para tratar la depresión
MX2020004467A (es) Metodos para el tratamiento o la prevencion del asma mediante la administracion de antagonista de il-4r.
CL2019003091A1 (es) Terapia de combinación.
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
AR105712A1 (es) Composiciones de insulina de rápida acción
BR112017017448A2 (pt) métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho
AR101740A1 (es) Terapia de combinación y composiciones
MX2019003703A (es) Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
CL2016002276A1 (es) Composiciones tópicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112018015367A2 (pt) carreadores oromucosais de nanofibra para tratamento terapêutico
CL2020002544A1 (es) Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret
CO2020010013A2 (es) Terapia de combinación para tratar o prevenir el cáncer
CL2021001623A1 (es) Terapia de combinación con un inhibidor de raf y un inhibidor de cdk4/6 para utilizar en el tratamiento del cáncer
CL2019000625A1 (es) Combinación de agonistas de fxr.
AR111374A1 (es) Uso de lik066 en pacientes con insuficiencia cardíaca
AR119159A1 (es) Tratamientos de angioedema
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
MX2020001164A (es) Composicion para su uso en la prevencion y/o el tratamiento de la mucositis orogastrointestinal inducida por un tratamiento oncologico.
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
CL2022000790A1 (es) Método para tratar vih con cabotegravir y rilpivirina